Cytel Corporation Opens New Carbohydrate Manufacturing Facility; Site Customized for the Commercial Manufacture of Cylexin.SAN DIEGO--(BW HealthWire)--June 3, 1998--Cytel Corporation (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :CYTL) today announced it has opened a new 10,000 square foot facility in San Diego San Diego (săn dēā`gō), city (1990 pop. 1,110,549), seat of San Diego co., S Calif., on San Diego Bay; inc. 1850. San Diego includes the unincorporated communities of La Jolla and Spring Valley. Coronado is across the bay. for the commercial manufacture of its lead therapeutic compound, Cylexin, and other carbohydrate products. The new manufacturing and quality control site will enable Cytel to manufacture, process, freeze dry, and test large quantities of Cylexin in one location. The grand opening ribbon cutting event will be held today at the new location, according to Virgil Thompson, Cytel's president and chief executive officer. "We are pleased to enhance our Glytec(TM) carbohydrate manufacturing unit with this new customized facility," said Jim Paulson, Cytel's chief scientific officer and general manager of Glytec. "With this added site, we are now prepared to manufacture Cylexin in the quantities necessary for the completion of clinical trials and a commercial product launch. In addition, our Glytec business unit will use the facility to manufacture carbohydrate products using Cytel's novel SNC SNC St Norbert College (De Pere, Wisconsin) SNC Sistema Nervioso Central SNC Société en Nom Collectif (French: Partnership) SNC Système Nerveux Central (French: central nervous system) technology for corporate partners such as Baxter Healthcare's Nextran unit." Cylexin, a small molecule carbohydrate compound, is currently in Phase II/III clinical registration trials for the treatment of reperfusion injury reperfusion injury damage to renal blood vessels during periods of hypotension does not become apparent until reperfusion occurs in the recovery stage of the vascular incident. in infants undergoing cardiopulmonary bypass cardiopulmonary bypass n. A procedure to circulate and oxygenate the blood during heart surgery involving the diversion of blood from the heart and lungs through a heart-lung machine and the return of oxygenated blood to the aorta. surgery during the surgical repair of heart defects. Cytel anticipates enrollment in the trial to be completed by the end of 1998. In September 1996, Cytel entered into a strategic partnership agreement with Nextran for the development and manufacture of an alpha-galactose carbohydrate product. The product is currently in preclinical development at Nextran for the treatment of hyperacute rejection associated with xenotransplantation xen·o·trans·plan·ta·tion n. The surgical transfer of cells, tissues, or especially whole organs from one species to another. xenotransplantation , a procedure involving the transplant of animal organs into human recipients. In December 1997, the agreement was expanded to include the development and supply of additional carbohydrate products for similar uses. Sugar Nucleotide Cycling(TM) (SNC) technology is used for the assembly of complex and specific bioactive bi·o·ac·tive adj. Of or relating to a substance that has an effect on living tissue. bioactive having an effect on or eliciting a response from living tissue. carbohydrates on a commercial scale and is also useful for synthetic remodeling remodeling /re·mod·el·ing/ (re-mod´el-ing) reorganization or renovation of an old structure. bone remodeling of carbohydrates or recombinant glycoproteins. The technology imitates the natural carbohydrate synthesis process requiring a cascade of chemical reactions initiated by specialized enzymes. The method is more time and cost effective than chemical synthesis technologies. Cytel discovers and develops cell adhesion inhibitors for treatment of acute and chronic inflammation chronic inflammation n. Inflammation that may have a rapid or slow onset but is characterized primarily by its persistence and lack of clear resolution; it occurs when the tissues are unable to overcome the effects of the injuring agent. , and manufactures bioactive carbohydrates for use in medical and consumer products. Epimmune Inc., its subsidiary, is focused on the discovery and development of a new generation of safer, more potent vaccines for the prevention and treatment of cancer and infectious diseases. This press release includes forward-looking statements that reflect management's current views of future events. Actual results may differ materially from the above forward-looking statements due to a number of important factors, including but not limited to the risks associated with successfully negotiating and completing definitive agreements for any corporate collaboration, the timing and cost of conducting human clinical trials, the regulatory approval process, and the possibility that testing may reveal undesirable and unintended side effects Side effects Effects of a proposed project on other parts of the firm. or other characteristics that may prevent or limit the commercial use of proposed products. These factors are more fully discussed in Cytel's most recent Forms 10-K and 10-Q. CONTACT: Cytel Corporation Virgil Thompson, 619/552-3000 or Mentus, Inc. Linda Seaton/Kelly Steeves, 619/455-5500 ext. 133/129 Timothy Scott, 619/455-5500 ext. 132 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion